Current Allergy and Asthma Reports

, Volume 11, Issue 2, pp 173–177 | Cite as

The History of IgE: From Discovery to 2010



The discovery of IgE and the role of IgE-mediated inflammation gave clinical allergy a scientific backbone, and as a result, the reputation of the specialty allergy has increased considerably over the years. Allergy diagnosis was improved by assays for in vitro determination of the presence and concentration of IgE antibodies, and clinical knowledge also broadened, allowing better service for the increasing number of allergic individuals. Access to immune assays for allergens finally allowed characterization and standardization of allergen preparations used for diagnosis and allergen-specific immunotherapy. Improved basic molecular technologies have further increased our knowledge about the complex component composition of an allergen extract, introduced IgE-specific immunotherapy, and allowed the allergist to better handle even severe allergic reactions such as anaphylaxis.


IgE antibody ASIT ESIT CD-sens 



No potential conflict of interest relevant to this article was reported.


Papers of particular interest, published recently, have been highlighted as: ••Of major importance

  1. 1.
    Bostock J: Case of a periodical affection of the eyes and chest. Med Chir Trans 1819, 10:161.PubMedGoogle Scholar
  2. 2.
    Ramirez MA: Horse asthma following blood transfusion: Report on a case. JAMA 1919, 73:984–985.Google Scholar
  3. 3.
    Prausnitz C, Küstner H: Studien über die Überempfindlichkeit. Zentralbl Bakteriol I Abt Orig 1921, 86:160–169.Google Scholar
  4. 4.
    Coca AF, Cooke RA: On the classification of the phenomenon of hypersensitiveness. J Immunol 1923, 8:163–182.Google Scholar
  5. 5.
    Ishizaka K, Ishizaka T, Hathorn EM: Blocking of Prausnitz-Küstner sensitization with reagin by “A chain“ of human γ1A-globulin. Immunochemistry 1964, 1:197–207.PubMedCrossRefGoogle Scholar
  6. 6.
    Ishizaka K, Ishizaka T: Identification of γE-antibodies as a carrier of reaginic activity. J Immunol 1967, 99:1187.PubMedGoogle Scholar
  7. 7.
    Rowe DS, Fahey JL: A new class of human immunoglobulins. II. Normal serum IgD. J Exp Med 1965, 121:185–199.PubMedCrossRefGoogle Scholar
  8. 8.
    Stanworth DR, Humphrey JH, Bennich H, Johansson SGO: Specific inhibition of the Prausnitz-Küstner reaction by an atypical human myeloma protein. Lancet 1967, 2:330–332.PubMedCrossRefGoogle Scholar
  9. 9.
    Johansson SGO: Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 1967, 2:951–953.PubMedCrossRefGoogle Scholar
  10. 10.
    Wide L, Bennich H, Johansson SGO: Diagnosis of allergy by an in-vitro test for allergen antibodies. Lancet 1967, 2:1105–1107.PubMedCrossRefGoogle Scholar
  11. 11.
    Bennich HH, Ishizaka K, Johansson SGO, et al.: Immunoglobulin E, a new class of human immunoglobulin. Bull World Health Organ 1968, 38:151–152.Google Scholar
  12. 12.
    Johansson SGO, Nopp A, van Hage M, et al.: Passive IgE-sensitization by blood transfusion. Allergy 2005, 60:1192–1199.PubMedCrossRefGoogle Scholar
  13. 13.
    Marsh DG: Allergens and the genetics of allergy. In: Sela M (ed.) The Antigens, vol. 3, Academic Press, New York, 1975, pp. 271–359.Google Scholar
  14. 14.
    Nopp A, Johansson SGO, Ankerst J, et al.: Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006, 61:298–302.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang H, Diepgen TL: Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 2005, 60:1098–1111.PubMedCrossRefGoogle Scholar
  16. 16.
    Lindelöf B, Granath F, Tengvall-Linder M, Ekbom A: Allergy and cancer. Allergy 2005, 60:1116–1120.Google Scholar
  17. 17.
    Vohlonen I, Terho EO, Koivikko A, et al.: Reproducibility of the skin prick test. Allergy 1989, 44:525–531.PubMedCrossRefGoogle Scholar
  18. 18.
    Nelson HS, Oppenheimer J, Buchmeier A, et al.: An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass. J Allergy Clin Immunol 1996, 97:1193–1201.PubMedCrossRefGoogle Scholar
  19. 19.
    Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities associated with immunotherapy and skin testing. J Allergy Clin Immunol 1987, 79:660–677.PubMedCrossRefGoogle Scholar
  20. 20.
    Sampson HA, Ho DG: Relationship between food specific IgE concentrations and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol 1997, 100:444–451.PubMedCrossRefGoogle Scholar
  21. 21.
    Sampson HA: Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001, 107:891–896.PubMedCrossRefGoogle Scholar
  22. 22.
    Nopp A, Johansson SGO, Lundberg M, Öman H: Simultaneous exposure of several allergens has an additive effect on multisensitized basophils. Allergy 2006, 61:1366–1368.PubMedCrossRefGoogle Scholar
  23. 23.
    Wahn U, Martin C, Freeman P, et al.: Relationship between pre-treatment specific IgE and the response to omalizumab therapy. Allergy 2009, 64:1780–1987.PubMedCrossRefGoogle Scholar
  24. 24.
    Valenta R, Lidholm J, Niederberger V, et al.: The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999, 29:896–904.PubMedCrossRefGoogle Scholar
  25. 25.
    Florvaag E, Johansson SGO: The pholcodine story. Immunol Allergy Clin North Am 2009, 29:419–427.PubMedCrossRefGoogle Scholar
  26. 26.
    •• Valenta R, Ferreira F, Focke-Tejkl M, et al.: From allergen genes to allergy vaccines. Ann Rev Immunol 2010, 28:211–241. This is an important summary of recent developments related to allergens. CrossRefGoogle Scholar
  27. 27.
    Holgate ST, Chuchalin AG, Herbert J, et al.: Efficacy and safety of a recombinant anti-IgE antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632–638.PubMedCrossRefGoogle Scholar
  28. 28.
    Kleine-Tebbe J, Erdmann S, Knol EF, et al.: Diagnostic tests based human basophils: Potentials, pitfalls and perspectives. Int Arch Allergy Clin Immunol 2006, 141:79–90.CrossRefGoogle Scholar
  29. 29.
    •• Johansson SGO, Nopp A, Öman H, et al.: The size of the disease relevant IgE antibody fraction in relation to “total-IgE” predicts the efficacy of anti-IgE (Xolair®) treatment. Allergy 2009, 64:1472–1477. This study proofs that the dosage of anti-IgE must be linked to the size of the IgE antibody fraction. PubMedCrossRefGoogle Scholar
  30. 30.
    Eckman JA, Sterba PM, Kelly D, et al.: Effects of Omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 2010, 125:889–895.PubMedCrossRefGoogle Scholar
  31. 31.
    Johansson SGO, Öman H, Nopp A, Pettersson S: The importance of IgE antibody levels in anti-IgE treatment. Allergy 2006, 61:1216–1219.PubMedCrossRefGoogle Scholar
  32. 32.
    Johansson SGO, Hourihane JO, Bousquet J, et al.: A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2001, 56:813–824.PubMedCrossRefGoogle Scholar
  33. 33.
    •• Johansson SGO, Bieber, T, Dahl R, et al.: Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004, 113:832–836. Without one and the same nomenclature we cannot communicate.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Clinical Immunology and Transfusion MedicineKarolinska University HospitalStockholmSweden

Personalised recommendations